Novo
Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion Other OTC:EMIS
ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) — Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk A/S (“Novo Nordisk”), whereby Novo Nordisk will acquire Emisphere, on a cash-free, debt-free basis, for $1.35 billion in cash. The consideration to be paid per share will …
Helius Medical Technologies, Inc. Provides Update on FDA’s Review of its Request for De Novo Classification and Clearance of the PoNS™ Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis
NEWTOWN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has received a request for additional information from the U.S. Food and Drug Administration (the “FDA” or “Agency”) related to the Company’s request for de novo …
SRK and Novo combine to bring breakthrough sampling technology to Australia
SRK Consulting (Australasia) Pty Ltd and Novo Resources Corp. have teamed up to trial an innovative groundwater sampling method, believed to be a first in the Australian mining industry. SRK has been conducting monthly and quarterly groundwater quality sampling at Novo’s four exploration sites in the Pilbara, Western Australia, since February 2018. The consultant has …
BGI Group Introduces New Technology Standard and Cost-Effective Solution for High Quality Haplotype-phased De Novo Human Genome Assembly
The new BGI standard 676 Quality Genome helps deliver on the promise of personalized medicine by providing more accurate and comprehensive genetic predictions, since it assembles each person’s genome individually and is not dependent on a reference genome, said Rade Drmanac, MGI Chief Scientific Officer, who presented the specifications during a talk at the European …
